Skip to main content
SpringerLink
Log in

Interferon antibodies in patients with infectious diseases

Anti-interferon antibodies

  • Published:
Biotherapy

Abstract

Interferons (IFNs) are generally recognized as the most important therapeutic agent in some infectious diseases such as chronic hepatitis B and C. Since the early clinical trials it was documented that the therapeutic use of IFNs could be complicated by the development of antibodies able to neutralize or to bind to the IFN molecule.

After several years of research it is now widely accepted that the presence of circulating anti-IFN antibodies may affect the response to IFN.

Here we summarize what is currently know on the clinical significance of antibodies to IFN in IFN-treated viral diseases patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ALT:

Alanine transaminase

ANB:

Antiviral neutralization bioassay

IFN:

Interferon

References

  1. Dianzani F. How to use an endogenous system as a therapeutic agent. J Interferon Res 1992; Special issue: 109–18

  2. Vallbracht A, Treuner T, Flehming B, Joester KE, Niethammer D. Interferon neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 1981; 287: 496–8.

    Article  Google Scholar 

  3. Antonelli G. Development of neutralizing and binding antibodies to interferon (IFN) in patients undergoing IFN therapy. Antiv Res 1994;24:235–44.

    Article  CAS  Google Scholar 

  4. Trown PW, Kramer MJ, Dennin RA Jr, Connel EV, Palleroni AV, Quesada J, Gutterman JU. Antibodies to human leucocyte interferons in cancer patients. Lancet 1983; 81–4.

  5. Panem S. Antibodies to interferon in man. Interferons and the immune system 1984; p. 175–183, Elsevier Amsterdam

  6. De Maeyer-Guignard J, De Maeyer E. Natural antibodies to Interferon-alpha and Interferon-beta are a common feature of inbread mouse strains. J Immunol 1986; 136: 1708–11.

    PubMed  Google Scholar 

  7. Caruso A, Bonfanti C, Colombrita D, et al. Natural antibodies to IFN-gamma in man and their increase during viral infection. J Immunol 1990; 144: 685–90.

    PubMed  CAS  Google Scholar 

  8. Ikeda Y, et al. Naturally occurring anti-interferon alpha 2a antibodies in patients with acute viral hepatitis. Clin. Exp. Immunol. 1991; 85: 80–4.

    Article  PubMed  CAS  Google Scholar 

  9. Ross C, Svenson M, Hansen MB, Vejlsgaard GL, Bendtzen K. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J. Clin. Invest. 1995; 95: 1974–8.

    Article  PubMed  CAS  Google Scholar 

  10. Avrameas S. Natural autoantibodies: from “horror autotoxicus” to “gnothi seauton”. Immunol Today 1991; 12: 154–9.

    PubMed  CAS  Google Scholar 

  11. Bendtzen K, Svenson M, Jonsson V, Hippe E. Autoantibodies to cytokines friends or foes? Immunol Today 1990; 11: 167–9.

    Article  PubMed  CAS  Google Scholar 

  12. Brook MG, McDonald JA, Karayannis P et al. Randomised controlled trial of interferon alpha 2a (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 1989; 30: 1116–22.

    PubMed  CAS  Google Scholar 

  13. Porres JC, Carreno V, Ruiz M, Marron JA, Bartolom J. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. Hepatol. 1989; 8: 351–7.

    Article  CAS  Google Scholar 

  14. Lok ASF, Lai CL, Leung KY. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatol. 1990; 12: 1266–70.

    Article  CAS  Google Scholar 

  15. Craxi A, Di Marco V, Volpes R, Palazzo U. Anti-alpha interferon antibodies after alpha interferon treatment in patients with chronic viral hepatitis. Hepato-Gastroenterol 1988; 35: 304–5.

    CAS  Google Scholar 

  16. Perillo RP, Schiff ER, Davis GL, et al. A randomized controlled trial of interferon alpha 2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Eng J Med 1990; 323: 295–301.

    Article  Google Scholar 

  17. Thurmond LM, Reese MJ. Immunochemical characterization of human antibodies to lymphoblastoid interferon. Clin Exp Immunol 1991; 86: 514–9.

    Article  PubMed  CAS  Google Scholar 

  18. Teitelbaum AP, Langton BC, Hung J et al. Antibody measurements in patients treated with recombinant interferon-beta. Proc AACR 1987; 28: 406.

    Google Scholar 

  19. Liao MJ, Axelrod HR, Kuchler M, Yip YK, Kirkbright E, Testa D. Absence of neutralizing antibodies to interferon in condyloma acuminata and cancer patients treated with natural human leukocyte interferon. J. Infect. Dis. 1992; 165: 757–60.

    PubMed  CAS  Google Scholar 

  20. Bonetti P, Diodati G, Drago C et al. Interferon antibodies in patients with chronic hepatitis C virus infection treated with recombinant interferon alpha-2a. Hepatol. 1994; 20: 416–20.

    Article  CAS  Google Scholar 

  21. Roffi L, Colloredo-Mels G, Antonelli G, et al. Breakthrough during recombinant alpha-interferon therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatol 1995; 21: 645–9. roffi

    Article  CAS  Google Scholar 

  22. Antonelli G, Currenti M, Turriziani O, Dianzani F. Neutralizing antibodies to interferon alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991; 163: 882–5.

    PubMed  CAS  Google Scholar 

  23. Antonelli G, Currenti M, Turriziani O, Riva E, Dianzani F. Relative frequency of non-neutralizing antibodies to interferon in hepatitis patients treated with different IFN alpha preparations. J Infect Dis 1992; 165: 593–4.

    PubMed  CAS  Google Scholar 

  24. Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberber C, Longo DL. Resistance to recombinant interferon alpha- -2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies. N. Eng. J. Med. 1988; 318: 1409–13.

    Article  CAS  Google Scholar 

  25. Figlin RA, Itri LM. Anti-Interferon antibodies: A perspective. Semin Hematol 1988; 25: 9–15.

    PubMed  CAS  Google Scholar 

  26. von Wussow P, Jalschies D, Freund M, and Deicher H. Humoral response to recombinant interferon alpha 2b: results of comparative assay and clinical perspectives J. Interferon Res. 1989; 9: S25–31.

    Google Scholar 

  27. Larocca AP, Steven CL, Stephen GM, Colby CB, Borden EC. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta. J. Interferon Res. 1989; 9: S51–60.

    PubMed  Google Scholar 

  28. Lok ASF; Lai CL, Wu PC, Leung EKY. Long -term follow up in a randomized controlled trial of recombinant alpha-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; ii: 298–302.

    Article  Google Scholar 

  29. Jacobs S, Friedman RM, Nagabhushan TL, Oden E, Salfi M, Bordens R, Spiegel R. Detection of serum neutralizing antibodies to interferon alfa-2b (Intron A) by means of an enzyme immunoassay. J Interferon Res 1989; 9: S292.

  30. Finter NB,. Why are there so many subtypes of alpha-interferons? J. Interferon Res. (Speciale issue) 1991; 185–94.

  31. Palleroni A, Aglione A, Labow M et al. Preclinical evaluation of interferon immunogenicity. J Interferon Res 1994; 14(1): S128.

    Google Scholar 

  32. Scott Crowe J, Gewert DR, Barber KA, et al. Interferon (IFN)-alpha 2 genotype analysis of chinese chronic hepatitis B patients undergoing recombinant IFN.alpha2a therapy. J Infect Dis 1994; 169:875–8.

    Google Scholar 

  33. Antonelli et al. (Manuscript in preparation)

  34. Fierlbeck G, Schreiner T, Schabern B et al. Neutralizing interferon beta antibodies in melanoma patients treated with recombinant natural interferon beta. Cancer Immunol Immunoth. 1994;39:263–8.

    CAS  Google Scholar 

  35. Dummer R, Muller W, Nestle F, et al. Formation of neutralizing antibodies against natural Interferon-beta, but not against recombinant Interferon-gamma during adiuvant therapy for high-risk malignant melanoma patients. Cancer 1991; 67: 2300–4.

    Article  PubMed  CAS  Google Scholar 

  36. The IFN Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-rimitting multiple sclerosis. Neurol. 1993; 43: 655–61.

    Google Scholar 

  37. Jaffe HS, Chen AB, Kramer S, Sherwin SA. The absence of interferon antibody formation in patients receiving human interferon- gamma. J. Interferon Res. 1987; 6: 576–80.

    CAS  Google Scholar 

  38. Giannelli G, Antonelli G, Fera G, Del Vecchio S, Riva E, Broccia C, Schiraldi O, Dianzani F. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C. Clin. Exp. Immunol. 1994; 97: 4–9.

    Article  PubMed  CAS  Google Scholar 

  39. Antonelli G, Giannelli G, Currenti M et al. Fate of antibody to interferon (IFN) in chronic hepatitis C patients treated with recombinant IFN alpha 2 and retreated with lymphoblastoid IFN alpha. Intern Hepatol Commun 1995; 4: 232–7.

    Article  Google Scholar 

  40. Ronnblom LE, Janson ET, Perers A, Oberg KE, Alm GV. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment. Clin. Exp. Immunol. 1992; 89: 330–5.

    PubMed  CAS  Google Scholar 

  41. Brand CM, Leadbeater L, Bellati G, Marotta F, Ideo G. Antibodies developing against a single recombinant interferon protein may neutralize other interferon-alpha subtypes. J Interferon Res 1993; 13: 121–5.

    PubMed  CAS  Google Scholar 

  42. Nolte KU, et al. Human therapy-unduced anti-IFN alpha antibodies neutralize rIFN-alpha2 by binding to its N-terminal functional domain. J. Interferon Res. 1994; 14: S118.

    Google Scholar 

  43. Quesada J, Rios A, Swanson D, Gutterman JU. Antitumor activity of recombinant derived interferon alpha in metastatic renal cell carcinoma. J. Clin. Oncol. 1985; 3: 1522–29.

    PubMed  CAS  Google Scholar 

  44. Milella M, Antonelli G, Santantonio T, Currenti M, Monno L, Mariano N, Angarano G, Dianzani F, Pastore G. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver 1993; 13: 146–60.

    PubMed  CAS  Google Scholar 

  45. Antonelli G, Giannelli G, Currenti M, et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant iFN alpha 2 therapy. Clin Exp Immunol 1996; 104: 384–87.

    Article  PubMed  CAS  Google Scholar 

  46. Milella M, Antonelli G, Santantonio T, et al. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN. J Hepato-Gastroenterol 1995; 42: 201–4.

    CAS  Google Scholar 

  47. Colloredo-Mels G, Roffi L, Antonelli G, et al. Lymphoblastoid interferon in patients with chronic nAnB hepatitis showing relapse during recombinant alpha interferon therapy. Hepatitis Delta Virus, Wiley-Liss, Inc 1993; 359–64.

  48. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77–81.

    Article  PubMed  CAS  Google Scholar 

  49. Nakajima S, Kuroki T, Shintani M, et al. Changes in interferon receptors on peripheral blood mononuclear cells from patients with chronic hepatitis B being treated with interferon. Hepatol 1990; 12: 1261–65.

    Article  CAS  Google Scholar 

  50. Rosenblum MG, Unger BW, Gutermab JU, Hersh EM, David GS, Frincke JM. Modification of human leukocyte interferon pharmacology with a monoclonal antibody. Cancer Res. 1985; 45: 2421–5.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedicine, University of Pisa, Pisa

    G. Antonelli & M. Pistello

  2. Instituto di Virologia, Università “La Sapienza”, Viale di Porta Tiburtina, 28 00185, Roma

    E. Simeoni, M. Currenti & F. Dianzani

  3. Department of Biology, University “Tor Vergata”, Rome, Italy

    F. De Pisa & V. Colizzi

Authors
  1. G. Antonelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Simeoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Currenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. De Pisa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Colizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Pistello
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Dianzani
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Antonelli, G., Simeoni, E., Currenti, M. et al. Interferon antibodies in patients with infectious diseases. Biotherapy 10, 7–14 (1997). https://doi.org/10.1007/BF02678212

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02678212

Key words

Search

Navigation